Skip to main content
Erschienen in:

15.01.2020 | Sarkome | Leitthema

Strategien bei gastrointestinalen Stromatumoren und intraabdominellen sowie retroperitonealen Sarkomen

verfasst von: PD Dr. med. Jens Jakob

Erschienen in: Die Onkologie | Ausgabe 3/2020

Einloggen, um Zugang zu erhalten

Zusammenfassung

Hintergrund

Die häufigsten abdominellen mesenchymalen Tumoren sind gastrointestinale Stromatumoren (GIST) und retroperitoneale bzw. intraabdominelle Sarkome.

Ziel

Im vorliegenden Artikel werden aktuelle Aspekte der Diagnostik (Biopsie) und Therapie sowie der Versorgungsstrukturen bei GIST und anderen abdominellen Sarkomen dargelegt.

Material und Methoden

Diese Arbeit basiert auf einer selektiven Literaturrecherche in der Datenbank PubMed zum Thema GIST und retroperitoneale und intraabdominelle Sarkome.

Ergebnisse

Aus der histologisch heterogenen Gruppe der intraabdominellen/retroperitonealen Weichgewebesarkome grenzen sich GIST aufgrund einer typischen Gain-of-Function-Mutation von Rezeptortyrosinkinasen ab. Für Letztere eröffnet sich hierdurch die Chance auf eine in randomisierten Studien geprüfte, gezielte Therapie. Die Therapieansätze bei anderen abdominellen Sarkomen sind dahingegen meist nicht molekular zielgerichtet und beruhen weitgehend auf Daten aus Kohortenstudien und randomisierten Studien bei Extremitätensarkomen.

Schlussfolgerung

Das unterschiedliche Management von GIST und anderen abdominellen Sarkomen ergibt sich aus der Etablierung der gezielten GIST-Therapie durch Tyrosinkinaseinhibitoren. Ansonsten wird das Therapiemanagement beider Entitäten durch die ihre Seltenheit bestimmt.
Literatur
1.
Zurück zum Zitat Ressing M et al (2018) Strengthening health data on a rare and heterogeneous disease: sarcoma incidence and histological subtypes in Germany. BMC Public Health 18(1):235PubMedPubMedCentral Ressing M et al (2018) Strengthening health data on a rare and heterogeneous disease: sarcoma incidence and histological subtypes in Germany. BMC Public Health 18(1):235PubMedPubMedCentral
2.
Zurück zum Zitat Mastrangelo G et al (2012) Incidence of soft tissue sarcoma and beyond: a population-based prospective study in 3 European regions. Cancer 118(21):5339–5348PubMed Mastrangelo G et al (2012) Incidence of soft tissue sarcoma and beyond: a population-based prospective study in 3 European regions. Cancer 118(21):5339–5348PubMed
3.
Zurück zum Zitat Toro JR et al (2006) Incidence patterns of soft tissue sarcomas, regardless of primary site, in the surveillance, epidemiology and end results program, 1978–2001: An analysis of 26,758 cases. Int J Cancer 119(12):2922–2930PubMed Toro JR et al (2006) Incidence patterns of soft tissue sarcomas, regardless of primary site, in the surveillance, epidemiology and end results program, 1978–2001: An analysis of 26,758 cases. Int J Cancer 119(12):2922–2930PubMed
4.
Zurück zum Zitat Blay JY et al (2019) Surgery in reference centers improves survival of sarcoma patients: a nationwide study. Ann Oncol 30(7):1143–1153PubMedPubMedCentral Blay JY et al (2019) Surgery in reference centers improves survival of sarcoma patients: a nationwide study. Ann Oncol 30(7):1143–1153PubMedPubMedCentral
5.
Zurück zum Zitat Blay JY et al (2017) Improved survival using specialized multidisciplinary board in sarcoma patients. Ann Oncol 28(11):2852–2859PubMedPubMedCentral Blay JY et al (2017) Improved survival using specialized multidisciplinary board in sarcoma patients. Ann Oncol 28(11):2852–2859PubMedPubMedCentral
7.
Zurück zum Zitat von Mehren M et al (2018) Soft Tissue Sarcoma, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 16(5):536–563 von Mehren M et al (2018) Soft Tissue Sarcoma, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 16(5):536–563
8.
Zurück zum Zitat Casali PG et al (2018) Soft tissue and visceral sarcomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 29(Supplement_4):iv51–iv67PubMed Casali PG et al (2018) Soft tissue and visceral sarcomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 29(Supplement_4):iv51–iv67PubMed
9.
Zurück zum Zitat Berger-Richardson D, Swallow CJ (2017) Needle tract seeding after percutaneous biopsy of sarcoma: risk/benefit considerations. Cancer 123(4):560–567PubMed Berger-Richardson D, Swallow CJ (2017) Needle tract seeding after percutaneous biopsy of sarcoma: risk/benefit considerations. Cancer 123(4):560–567PubMed
10.
Zurück zum Zitat Van Houdt WJ et al (2017) Needle tract seeding following core biopsies in retroperitoneal sarcoma. Eur J Surg Oncol 43(9):1740–1745PubMed Van Houdt WJ et al (2017) Needle tract seeding following core biopsies in retroperitoneal sarcoma. Eur J Surg Oncol 43(9):1740–1745PubMed
11.
Zurück zum Zitat Trindade AJ et al (2019) Fine-needle biopsy is superior to fine-needle aspiration of suspected gastrointestinal stromal tumors: a large multicenter study. Endosc Int Open 7(7):E931–E936PubMedPubMedCentral Trindade AJ et al (2019) Fine-needle biopsy is superior to fine-needle aspiration of suspected gastrointestinal stromal tumors: a large multicenter study. Endosc Int Open 7(7):E931–E936PubMedPubMedCentral
12.
Zurück zum Zitat Eriksson M et al (2016) Needle biopsy through the abdominal wall for the diagnosis of gastrointestinal stromal tumour – Does it increase the risk for tumour cell seeding and recurrence? Eur J Cancer 59:128–133PubMed Eriksson M et al (2016) Needle biopsy through the abdominal wall for the diagnosis of gastrointestinal stromal tumour – Does it increase the risk for tumour cell seeding and recurrence? Eur J Cancer 59:128–133PubMed
13.
Zurück zum Zitat Suman P et al (2017) Preoperative adrenal biopsy does not affect overall survival in adrenocortical carcinoma. Am J Surg 214(4):748–751PubMed Suman P et al (2017) Preoperative adrenal biopsy does not affect overall survival in adrenocortical carcinoma. Am J Surg 214(4):748–751PubMed
14.
Zurück zum Zitat Holmebakk T et al (2018) Recurrence-free survival after resection of gastric gastrointestinal stromal tumors classified according to a strict definition of tumor rupture: a population-based study. Ann Surg Oncol 25(5):1133–1139PubMed Holmebakk T et al (2018) Recurrence-free survival after resection of gastric gastrointestinal stromal tumors classified according to a strict definition of tumor rupture: a population-based study. Ann Surg Oncol 25(5):1133–1139PubMed
15.
Zurück zum Zitat Nishida T et al (2019) Defining tumor rupture in gastrointestinal stromal tumor. Ann Surg Oncol 26(6):1669–1675PubMedPubMedCentral Nishida T et al (2019) Defining tumor rupture in gastrointestinal stromal tumor. Ann Surg Oncol 26(6):1669–1675PubMedPubMedCentral
16.
Zurück zum Zitat Dematteo RP et al (2009) Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial. Lancet 373(9669):1097–1104PubMedPubMedCentral Dematteo RP et al (2009) Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial. Lancet 373(9669):1097–1104PubMedPubMedCentral
17.
Zurück zum Zitat Joensuu H et al (2012) One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial. JAMA 307(12):1265–1272PubMed Joensuu H et al (2012) One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial. JAMA 307(12):1265–1272PubMed
18.
Zurück zum Zitat Casali PG et al (2015) Time to definitive failure to the first Tyrosine kinase inhibitor in localized GI Stromal tumors treated with Imatinib as an Adjuvant: a European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group intergroup randomized trial in collaboration with the Australasian Gastro-Intestinal Trials Group, UNICANCER, French Sarcoma Group, Italian Sarcoma Group, and Spanish Group for Research on Sarcomas. J Clin Oncol 33(36):4276–4283PubMed Casali PG et al (2015) Time to definitive failure to the first Tyrosine kinase inhibitor in localized GI Stromal tumors treated with Imatinib as an Adjuvant: a European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group intergroup randomized trial in collaboration with the Australasian Gastro-Intestinal Trials Group, UNICANCER, French Sarcoma Group, Italian Sarcoma Group, and Spanish Group for Research on Sarcomas. J Clin Oncol 33(36):4276–4283PubMed
19.
Zurück zum Zitat Jakob J, Hohenberger P (2018) Neoadjuvant therapy to downstage the extent of resection of gastrointestinal Stromal tumors. Visc Med 34(5):359–365PubMedPubMedCentral Jakob J, Hohenberger P (2018) Neoadjuvant therapy to downstage the extent of resection of gastrointestinal Stromal tumors. Visc Med 34(5):359–365PubMedPubMedCentral
20.
Zurück zum Zitat Yoo C et al (2010) Cross-sectional study of imatinib plasma trough levels in patients with advanced gastrointestinal stromal tumors: impact of gastrointestinal resection on exposure to imatinib. J Clin Oncol 28(9):1554–1559PubMed Yoo C et al (2010) Cross-sectional study of imatinib plasma trough levels in patients with advanced gastrointestinal stromal tumors: impact of gastrointestinal resection on exposure to imatinib. J Clin Oncol 28(9):1554–1559PubMed
21.
Zurück zum Zitat Joensuu H et al (2017) Effect of KIT and PDGFRA mutations on survival in patients with gastrointestinal Stromal tumors treated with adjuvant Imatinib: an exploratory analysis of a randomized clinical trial. JAMA Oncol 3(5):602–609PubMedPubMedCentral Joensuu H et al (2017) Effect of KIT and PDGFRA mutations on survival in patients with gastrointestinal Stromal tumors treated with adjuvant Imatinib: an exploratory analysis of a randomized clinical trial. JAMA Oncol 3(5):602–609PubMedPubMedCentral
22.
Zurück zum Zitat Demetri GD et al (2006) Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 368(9544):1329–1338PubMed Demetri GD et al (2006) Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 368(9544):1329–1338PubMed
23.
Zurück zum Zitat Demetri GD et al (2013) Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 381(9863):295–302PubMed Demetri GD et al (2013) Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 381(9863):295–302PubMed
24.
Zurück zum Zitat Kang YK et al (2013) Resumption of imatinib to control metastatic or unresectable gastrointestinal stromal tumours after failure of imatinib and sunitinib (RIGHT): a randomised, placebo-controlled, phase 3 trial. Lancet Oncol 14(12):1175–1182PubMedPubMedCentral Kang YK et al (2013) Resumption of imatinib to control metastatic or unresectable gastrointestinal stromal tumours after failure of imatinib and sunitinib (RIGHT): a randomised, placebo-controlled, phase 3 trial. Lancet Oncol 14(12):1175–1182PubMedPubMedCentral
25.
Zurück zum Zitat Garner AP et al (2014) Ponatinib inhibits polyclonal drug-resistant KIT oncoproteins and shows therapeutic potential in heavily pretreated gastrointestinal stromal tumor (GIST) patients. Clin Cancer Res 20(22):5745–5755PubMedPubMedCentral Garner AP et al (2014) Ponatinib inhibits polyclonal drug-resistant KIT oncoproteins and shows therapeutic potential in heavily pretreated gastrointestinal stromal tumor (GIST) patients. Clin Cancer Res 20(22):5745–5755PubMedPubMedCentral
26.
Zurück zum Zitat Smith BD et al (2019) Ripretinib (DCC-2618) is a switch control kinase inhibitor of a broad spectrum of oncogenic and drug-resistant KIT and PDGFRA variants. Cancer Cell 35(5):738–751.e9PubMed Smith BD et al (2019) Ripretinib (DCC-2618) is a switch control kinase inhibitor of a broad spectrum of oncogenic and drug-resistant KIT and PDGFRA variants. Cancer Cell 35(5):738–751.e9PubMed
27.
Zurück zum Zitat Gebreyohannes YK et al (2019) Robust activity of avapritinib, potent and highly selective inhibitor of mutated KIT, in patient-derived xenograft models of gastrointestinal Stromal tumors. Clin Cancer Res 25(2):609–618PubMed Gebreyohannes YK et al (2019) Robust activity of avapritinib, potent and highly selective inhibitor of mutated KIT, in patient-derived xenograft models of gastrointestinal Stromal tumors. Clin Cancer Res 25(2):609–618PubMed
28.
Zurück zum Zitat Bonvalot S et al (2012) Technical considerations in surgery for retroperitoneal sarcomas: position paper from E‑Surge, a master class in sarcoma surgery, and EORTC-STBSG. Ann Surg Oncol 19(9):2981–2991PubMed Bonvalot S et al (2012) Technical considerations in surgery for retroperitoneal sarcomas: position paper from E‑Surge, a master class in sarcoma surgery, and EORTC-STBSG. Ann Surg Oncol 19(9):2981–2991PubMed
29.
Zurück zum Zitat Harati K et al (2017) Soft tissue sarcomas of the extremities: surgical margins can be close as long as the resected tumor has no ink on it. Oncologist 22(11):1400–1410PubMedPubMedCentral Harati K et al (2017) Soft tissue sarcomas of the extremities: surgical margins can be close as long as the resected tumor has no ink on it. Oncologist 22(11):1400–1410PubMedPubMedCentral
30.
Zurück zum Zitat Gundle KR et al (2018) Analysis of Margin Classification Systems for Assessing the Risk of Local Recurrence After Soft Tissue Sarcoma Resection. J Clin Oncol 36(7):704–709PubMed Gundle KR et al (2018) Analysis of Margin Classification Systems for Assessing the Risk of Local Recurrence After Soft Tissue Sarcoma Resection. J Clin Oncol 36(7):704–709PubMed
31.
Zurück zum Zitat Jakob J, Hohenberger P (2019) Principles of sarcoma surgery. Pathologe 40(4):431–435PubMed Jakob J, Hohenberger P (2019) Principles of sarcoma surgery. Pathologe 40(4):431–435PubMed
32.
Zurück zum Zitat Bonvalot S et al (2019) Strass (EORTC 62092): A phase III randomized study of preoperative radiotherapy plus surgery versus surgery alone for patients with retroperitoneal sarcoma. J Clin Oncol 37(suppl):abstr 11001–2019 (in ASCO) Bonvalot S et al (2019) Strass (EORTC 62092): A phase III randomized study of preoperative radiotherapy plus surgery versus surgery alone for patients with retroperitoneal sarcoma. J Clin Oncol 37(suppl):abstr 11001–2019 (in ASCO)
33.
Zurück zum Zitat Haas RLM et al (2019) Radiotherapy for retroperitoneal liposarcoma: a report from the Transatlantic Retroperitoneal Sarcoma Working Group. Cancer 125(8):1290–1300PubMedPubMedCentral Haas RLM et al (2019) Radiotherapy for retroperitoneal liposarcoma: a report from the Transatlantic Retroperitoneal Sarcoma Working Group. Cancer 125(8):1290–1300PubMedPubMedCentral
34.
Zurück zum Zitat Gronchi A et al (2016) Variability in patterns of recurrence after resection of primary retroperitoneal sarcoma (RPS): a report on 1007 patients from the Multi-Institutional Collaborative RPS Working Group. Ann Surg 263(5):1002–1009PubMed Gronchi A et al (2016) Variability in patterns of recurrence after resection of primary retroperitoneal sarcoma (RPS): a report on 1007 patients from the Multi-Institutional Collaborative RPS Working Group. Ann Surg 263(5):1002–1009PubMed
35.
Zurück zum Zitat Woll PJ et al (2012) Adjuvant chemotherapy with doxorubicin, ifosfamide, and lenograstim for resected soft-tissue sarcoma (EORTC 62931): a multicentre randomised controlled trial. Lancet Oncol 13(10):1045–1054PubMed Woll PJ et al (2012) Adjuvant chemotherapy with doxorubicin, ifosfamide, and lenograstim for resected soft-tissue sarcoma (EORTC 62931): a multicentre randomised controlled trial. Lancet Oncol 13(10):1045–1054PubMed
36.
Zurück zum Zitat Pasquali S et al (2019) The impact of chemotherapy on survival of patients with extremity and trunk wall soft tissue sarcoma: revisiting the results of the EORTC-STBSG 62931 randomised trial. Eur J Cancer 109:51–60PubMed Pasquali S et al (2019) The impact of chemotherapy on survival of patients with extremity and trunk wall soft tissue sarcoma: revisiting the results of the EORTC-STBSG 62931 randomised trial. Eur J Cancer 109:51–60PubMed
37.
Zurück zum Zitat Raut CP et al (2016) External validation of a multi-institutional retroperitoneal sarcoma nomogram. Cancer 122(9):1417–1424PubMed Raut CP et al (2016) External validation of a multi-institutional retroperitoneal sarcoma nomogram. Cancer 122(9):1417–1424PubMed
38.
Zurück zum Zitat Nagasubramanian R et al (2016) Infantile fibrosarcoma with NTRK3-ETV6 fusion successfully treated with the tropomyosin-related kinase inhibitor LOXO-101. Pediatr Blood Cancer 63(8):1468–1470PubMedPubMedCentral Nagasubramanian R et al (2016) Infantile fibrosarcoma with NTRK3-ETV6 fusion successfully treated with the tropomyosin-related kinase inhibitor LOXO-101. Pediatr Blood Cancer 63(8):1468–1470PubMedPubMedCentral
39.
Zurück zum Zitat Gronchi A et al (2017) Histotype-tailored neoadjuvant chemotherapy versus standard chemotherapy in patients with high-risk soft-tissue sarcomas (ISG-STS 1001): an international, open-label, randomised, controlled, phase 3, multicentre trial. Lancet Oncol 18(6):812–822PubMed Gronchi A et al (2017) Histotype-tailored neoadjuvant chemotherapy versus standard chemotherapy in patients with high-risk soft-tissue sarcomas (ISG-STS 1001): an international, open-label, randomised, controlled, phase 3, multicentre trial. Lancet Oncol 18(6):812–822PubMed
40.
Zurück zum Zitat Perrier L et al (2012) Clinicians’ adherence versus non adherence to practice guidelines in the management of patients with sarcoma: a cost-effectiveness assessment in two European regions. BMC Health Serv Res 12:82PubMedPubMedCentral Perrier L et al (2012) Clinicians’ adherence versus non adherence to practice guidelines in the management of patients with sarcoma: a cost-effectiveness assessment in two European regions. BMC Health Serv Res 12:82PubMedPubMedCentral
41.
Zurück zum Zitat Bonvalot S et al (2019) Survival benefit of the surgical management of retroperitoneal sarcoma in a reference center: a nationwide study of the French Sarcoma Group from the netSarc database. Ann Surg Oncol 26(7):2286–2293PubMed Bonvalot S et al (2019) Survival benefit of the surgical management of retroperitoneal sarcoma in a reference center: a nationwide study of the French Sarcoma Group from the netSarc database. Ann Surg Oncol 26(7):2286–2293PubMed
42.
Zurück zum Zitat Jakob J et al (2018) Treatment of retroperitoneal sarcoma in Germany : results of a survey of the German Society of General and Visceral Surgery, the German Interdisciplinary Sarcoma Study Group and the advocacy group Das Lebenshaus. Chirurg 89(1):50–55PubMed Jakob J et al (2018) Treatment of retroperitoneal sarcoma in Germany : results of a survey of the German Society of General and Visceral Surgery, the German Interdisciplinary Sarcoma Study Group and the advocacy group Das Lebenshaus. Chirurg 89(1):50–55PubMed
43.
Zurück zum Zitat Honore C et al (2017) Abdominal desmoplastic small round cell tumor without extraperitoneal metastases: Is there a benefit for HIPEC after macroscopically complete cytoreductive surgery? PLoS ONE 12(2):e171639PubMedPubMedCentral Honore C et al (2017) Abdominal desmoplastic small round cell tumor without extraperitoneal metastases: Is there a benefit for HIPEC after macroscopically complete cytoreductive surgery? PLoS ONE 12(2):e171639PubMedPubMedCentral
44.
Zurück zum Zitat Honore C et al (2019) Can we cure patients with abdominal desmoplastic small round cell tumor? Results of a retrospective multicentric study on 100 patients. Surg Oncol 29:107–112PubMed Honore C et al (2019) Can we cure patients with abdominal desmoplastic small round cell tumor? Results of a retrospective multicentric study on 100 patients. Surg Oncol 29:107–112PubMed
Metadaten
Titel
Strategien bei gastrointestinalen Stromatumoren und intraabdominellen sowie retroperitonealen Sarkomen
verfasst von
PD Dr. med. Jens Jakob
Publikationsdatum
15.01.2020
Verlag
Springer Medizin
Schlagwörter
Sarkome
GIST
Imatinib
Erschienen in
Die Onkologie / Ausgabe 3/2020
Print ISSN: 2731-7226
Elektronische ISSN: 2731-7234
DOI
https://doi.org/10.1007/s00761-019-00693-6

Weitere Artikel der Ausgabe 3/2020

Der Onkologe 3/2020 Zur Ausgabe

Leitthema

Kehlkopfkrebs

Neu im Fachgebiet Onkologie

Muskeln trainieren gegen Nervenschäden durch Chemotherapie

17.07.2024 Nebenwirkungen der Krebstherapie Nachrichten

Chemotherapien können die Nerven schädigen und damit die Lebensqualität von Betroffenen zusätzlich einschränken. Wer aber auf die richtige Art trainiert, kann das absolute Risiko für Neuropathien um bis zu 40% senken.

Die beste Jahreszeit für eine Krebsimmuntherapie

16.07.2024 Onkologische Immuntherapie Nachrichten

Die Wirksamkeit von Checkpointhemmern scheint klinisch relevanten saisonalen Schwankungen zu unterliegen. Patienten mit fortgeschrittenem nichtkleinzelligem Lungenkarzinom etwa hatten das beste Outcome, wenn die PD-1-Inhibitor-Infusionen in den Wintermonaten starteten.

Partielle Nephrektomie: Videoanalysen zur Verbesserung der chirurgischen Qualität

16.07.2024 Nephrektomie Nachrichten

Je versierter Operateurinnen und Operateure sind, desto geringer ist das Risiko für Komplikationen. Eine kleine US-Studie spricht dafür, dass das auch bei Roboter-assistierten Nephrektomien gilt – und dass sich Op.-Videos für die Beurteilung eignen.        

S3-Leitlinie Endometriumkarzinom aktualisiert

15.07.2024 Endometriumkarzinom Nachrichten

Die angepasste Version der S3-Leitlinie Endometriumkarzinom enthält unter anderem Empfehlungen zu Risikofaktoren, wie der Hormonersatztherapie, sowie darüber, wann eine vaginale Brachytherapie und wann eine Perkutanbestrahlung angebracht ist.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.